<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1555-7960</journal-id>
<journal-title><![CDATA[MEDICC Review]]></journal-title>
<abbrev-journal-title><![CDATA[MEDICC rev.]]></abbrev-journal-title>
<issn>1555-7960</issn>
<publisher>
<publisher-name><![CDATA[Medical Education Cooperation with Cuba]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1555-79602012000100004</article-id>
<article-id pub-id-type="doi">10.1590/S1555-79602012000100004</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Lipid levels as predictors of silent myocardial ischemia in a type 2 diabetic population in Havana]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Peña]]></surname>
<given-names><![CDATA[Yamilé]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fernández-Britto]]></surname>
<given-names><![CDATA[José E.]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bacallao]]></surname>
<given-names><![CDATA[Jorge]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Batista]]></surname>
<given-names><![CDATA[Juan F.]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[León]]></surname>
<given-names><![CDATA[María L. de]]></given-names>
</name>
<xref ref-type="aff" rid="A03"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,National Clinical Research Center  ]]></institution>
<addr-line><![CDATA[Havana ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="A02">
<institution><![CDATA[,Atherosclerosis Research and Reference Center  ]]></institution>
<addr-line><![CDATA[Havana ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="A03">
<institution><![CDATA[,Primero de Enero Polyclinic  ]]></institution>
<addr-line><![CDATA[Havana ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>01</month>
<year>2012</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>01</month>
<year>2012</year>
</pub-date>
<volume>14</volume>
<numero>1</numero>
<fpage>18</fpage>
<lpage>24</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielosp.org/scielo.php?script=sci_arttext&amp;pid=S1555-79602012000100004&amp;lng=en&amp;nrm=iso&amp;tlng=en"></self-uri><self-uri xlink:href="http://www.scielosp.org/scielo.php?script=sci_abstract&amp;pid=S1555-79602012000100004&amp;lng=en&amp;nrm=iso&amp;tlng=en"></self-uri><self-uri xlink:href="http://www.scielosp.org/scielo.php?script=sci_pdf&amp;pid=S1555-79602012000100004&amp;lng=en&amp;nrm=iso&amp;tlng=en"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[INTRODUCTION Silent myocardial ischemia is frequent in type 2 diabetics, therefore, symptoms cannot be relied upon for diagnosis and followup in these patients. Various studies relate blood lipid levels to cardiovascular diseases, and several authors describe certain lipoproteins as independent predictors of ischemia. OBJECTIVE Identify blood lipid levels that predict silent myocardial ischemia in a type 2 diabetic population in Havana. METHODS From May 2005 through May 2009, assessment was done of 220 asymptomatic type 2 diabetics in ten polyclinics in Havana using laboratory tests and Single-Photon Emission-Computed Tomography, synchronized with electrocardiogram, known as gated SPECT (gSPECT). Coronary angiography was used for confirmation when gSPECT detected ischemia. Patients were classified into two groups: gSPECT positive and gSPECT negative. Descriptive statistics (mean and standard deviation) were calculated for all variables and mean comparison tests were conducted. Classification trees were developed relating lipid values to gSPECT results, identifying optimal cutoff points for their use as indicators of silent myocardial ischemia in the total study population and for each sex separately. RESULTS GSPECT found silent myocardial ischemia in 29.1% of those examined, and 68.4% of angiograms found multivessel disease. gSPECT-positive diabetics had higher levels of total cholesterol, LDL, and triglycerides (p < 0.05). HDL levels were lower in this group (p < 0.05). Classification trees showed optimal cutoff points, indicators for silent ischemia, for: HDL <44 mg/dL, LDL &gt;119.9 mg/dL, and triglycerides &gt;107.2 mg/d; 80.4% of diabetics with these HDL and triglyceride values had ischemia. HDL was the most important normalized variable when the entire population was analyzed. Analysis by sex showed a greater percentage of silent ischemia in men (33.3%) than in women (24.8%). The most important normalized variables were LDL of &gt;100.8 mg/dL for men and HDL of <44 mg/dL for women. CONCLUSIONS A considerable percentage of the study population had silent myocardial ischemia. Type 2 diabetics with ischemia had higher levels of total cholesterol, LDL and triglycerides. HDL levels were significantly lower in these patients. The association of low HDL with high triglycerides was a strong indicator of myocardial ischemia in type 2 diabetics without clinical cardiovascular signs.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Lipids]]></kwd>
<kwd lng="en"><![CDATA[type 2 diabetes]]></kwd>
<kwd lng="en"><![CDATA[silent myocardial ischemia]]></kwd>
<kwd lng="en"><![CDATA[decision trees]]></kwd>
<kwd lng="en"><![CDATA[diagnostic imaging]]></kwd>
<kwd lng="en"><![CDATA[Single-Photon Emission-Computed Tomography]]></kwd>
<kwd lng="en"><![CDATA[cardiac-gated SPECT]]></kwd>
<kwd lng="en"><![CDATA[early detection]]></kwd>
<kwd lng="en"><![CDATA[Cuba]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[ <p align="right"><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>ORIGINAL    RESEARCH</b></font></p>     <p>&nbsp;</p>     <p><a name="top"></a><font face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Lipid    levels as predictors of silent myocardial ischemia in a type 2 diabetic population    in Havana</b></font></p>     <p>&nbsp;</p>     <p>&nbsp;</p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Yamil&eacute;    Pe&ntilde;a MD PhD<sup>I</sup>; Jos&eacute; E. Fern&aacute;ndez-Britto MD DrSc<sup>II</sup>;    Jorge Bacallao MS PhD<sup>III</sup>; Juan F. Batista MD<sup>IV</sup>; Mar&iacute;a    L. de Le&oacute;n MD<sup>V</sup></b></font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><sup>I</sup>Internist    specializing in nuclear medicine, with a doctorate in medical sciences. Associate    researcher, National Clinical Research Center (CIC), Havana, Cuba.(Corresponding    author: <a href="mailto:yamilepq@infomed.sld.cu">yamilepq@infomed.sld.cu</a>)    <br>   <sup>II</sup>Anatomical pathologist. Distinguished professor and senior researcher,    Atherosclerosis Research and Reference Center (CIRAH), Havana, Cuba    <br>   <sup>III</sup>Mathematician and biostatistician. Full professor, CIRAH, Havana,    Cuba    <br>   <sup>IV</sup>Internist specializing in nuclear medicine, CIC, Havana, Cuba    ]]></body>
<body><![CDATA[<br>   <sup>V</sup>Family physician, Primero de Enero Polyclinic, Havana, Cuba</font></p>     <p>&nbsp;</p>     <p>&nbsp;</p> <hr size="1" noshade>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b></font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>INTRODUCTION</b>    Silent myocardial ischemia is frequent in type 2 diabetics, therefore, symptoms    cannot be relied upon for diagnosis and followup in these patients. Various    studies relate blood lipid levels to cardiovascular diseases, and several authors    describe certain lipoproteins as independent predictors of ischemia.    <br>   <b>OBJECTIVE</b> Identify blood lipid levels that predict silent myocardial    ischemia in a type 2 diabetic population in Havana.    <br>   <b>METHODS</b> From May 2005 through May 2009, assessment was done of 220 asymptomatic    type 2 diabetics in ten polyclinics in Havana using laboratory tests and Single-Photon    Emission-Computed Tomography, synchronized with electrocardiogram, known as    gated SPECT (gSPECT). Coronary angiography was used for confirmation when gSPECT    detected ischemia. Patients were classified into two groups: gSPECT positive    and gSPECT negative. Descriptive statistics (mean and standard deviation) were    calculated for all variables and mean comparison tests were conducted. Classification    trees were developed relating lipid values to gSPECT results, identifying optimal    cutoff points for their use as indicators of silent myocardial ischemia in the    total study population and for each sex separately.    <br>   <b>RESULTS</b> GSPECT found silent myocardial ischemia in 29.1% of those examined,    and 68.4% of angiograms found multivessel disease. gSPECT-positive diabetics    had higher levels of total cholesterol, LDL, and triglycerides (p &lt; 0.05).    HDL levels were lower in this group (p &lt; 0.05). Classification trees showed    optimal cutoff points, indicators for silent ischemia, for: HDL <u>&lt;</u>44    mg/dL, LDL &gt;119.9 mg/dL, and triglycerides &gt;107.2 mg/d; 80.4% of diabetics    with these HDL and triglyceride values had ischemia. HDL was the most important    normalized variable when the entire population was analyzed. Analysis by sex    showed a greater percentage of silent ischemia in men (33.3%) than in women    (24.8%). The most important normalized variables were LDL of &gt;100.8 mg/dL    for men and HDL of <u>&lt;</u>44 mg/dL for women.    <br>   <b>CONCLUSIONS</b> A considerable percentage of the study population had silent    myocardial ischemia. Type 2 diabetics with ischemia had higher levels of total    cholesterol, LDL and triglycerides. HDL levels were significantly lower in these    patients. The association of low HDL with high triglycerides was a strong indicator    of myocardial ischemia in type 2 diabetics without clinical cardiovascular signs.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Keywords:</b>    Lipids, type 2 diabetes, silent myocardial ischemia, decision trees, diagnostic    imaging, Single-Photon Emission-Computed Tomography, cardiac-gated SPECT, early    detection, Cuba</font></p> <hr size="1" noshade>     ]]></body>
<body><![CDATA[<p>&nbsp;</p>     <p>&nbsp;</p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="3"><b>INTRODUCTION</b></font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Life expectancy    for type 2 diabetics is 30% shorter than for non-diabetics, and their primary    cause of death is cardiovascular disease, aggravated by the fact that the disease    tends to appear silently and frequently leads to sudden death.&#91;1&#93; Multiple    studies have demonstrated a prevalence of silent myocardial ischemia (SMI) in    type 2 diabetics ranging from 9% to 57%.&#91;2,3&#93; Paradoxically, in this    particular group of patients, there is early onset of ischemic heart disease    (IHD) but late diagnosis, due to the absence of overt clinical signs.&#91;2,3&#93;</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Alterations in    blood lipid concentrations are a serious threat to type 2 diabetics. Several    studies report a considerable decrease in cardiovascular complications and mortality    in diabetics following treatment of dyslipidemia.&#91;4,5&#93; Previous studies    have looked at the relationship between blood lipid levels and the presence    of SMI, and several authors have described certain lipoproteins as independent    predictors of IHD.&#91;5,6&#93; The lipid profile is a routine test for diabetic    patients and even though the atherogenic pattern in type 2 diabetes mellitus    (DM) is well identified, in which triglyceride levels increase and levels for    cholesterol associated with high density lipoproteins (HDL) are below the normal    reference range, blood lipids could provide the physician with a clue to the    need for more sensitive studies for early detection of SMI.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Altered myocardial    perfusion is one of the first manifestations of the ischemic cascade, which    proceeds through a series of alterations until angina pectoris appears, the    classic clinical manifestation of IHD, thus the importance of myocardial perfusion    studies to detect ischemia in asymptomatic patients whose baseline electrocardiogram    (ECG) and cardiac stress tests are negative.&#91;7&#93; These studies are even    more valuable for early diagnosis, timely assessment and improved prognosis    in type 2 diabetics, who frequently have damaged microcirculation.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Single-Photon Emission-Computed    Tomography synchronized with ECG (gated SPECT or gSPECT) is a non-invasive technique    that has demonstrated high sensitivity and specificity in acute coronary disease,    with a predictive value of 95% to 100%. For chronic IHD, it has 87% sensitivity    and 75% specificity.&#91;8&#93; The ability to perform myocardial perfusion    tomography synchronized with the R segment on ECG permits assessment of perfusion    and ventricular function in the same test.&#91;7&#93;</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">GSPECT contributes    a functional perspective to the analysis of myocardial perfusion, while coronary    angiography provides a precise description of the coronary epicardial tree,    detecting the presence, degree and extent of anatomic stenosis. Images provided    by cardiac imaging radiotracers reflect alterations in myocardial perfusion    and therefore translate the functional impact of reduced arterial diameter.    This feature fulfills several objectives, from diagnosis of IHD and followup    with medical or surgical treatment, to stratification of risk in patients after    acute myocardial infarction.&#91;7&#93;</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Classification    and regression tree (CRT) analysis provides both predictive and explanatory    models&#91;9&#93; and is among the most frequently used statistical methods    for identifying disease predictors. It involves an algorithm that produces binary    trees, repeatedly dividing the data into two sets so that data in each subset    are more homogeneous than in the previous set,&#91;9&#93; enabling detection    of predictor or indicator cutoff points for a given disease.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">In Cuba, DM is    the sixth most common hospital discharge diagnosis and is among the ten leading    causes of death, with a prevalence of 40.5 per 1000 population and a mortality    rate of 13.2 per 100,000 population.&#91;10&#93;</font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Studies in the    international literature have evaluated the predictive ability of risk factors    for IHD;&#91;11&#93; however, it is important to study populations of different    countries and their particular characteristics in relation to potential risk.    Every population has its peculiarities, with varying dietary patterns, customs,    economic opportunities, cultural levels and other factors.&#91;1,11&#93; There    have been few Cuban studies to date of gSPECT in diagnosis of silent ischemia    in high risk patients such as type 2 diabetics.&#91;5&#93; The objective of    this study was to identify blood lipid levels predictive of SMI in a population    of asymptomatic type 2 diabetics from several Havana health areas.</font></p>     <p>&nbsp;</p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="3"><b>METHODS</b></font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">A prospective,    observational, analytical study was conducted from May 2005 through May 2009.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">A group of 220    type 2 diabetic patients without clinical cardiovascular signs from ten family    physician offices in Plaza de la Revoluci&oacute;n and Playa municipalities    (19 de Abril and Primero de Enero polyclinics in Havana) was assessed. All diabetics    were examined in each clinic, but only those meeting specific criteria were    included in this study.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Inclusion criteria</b>    Type 2 diabetics of both sexes, aged <u>&gt;</u>18 years, without symptoms or    previous diagnosis of IHD. All patients met American Diabetes Association criteria    for cardiovascular disease screening (two or more major associated atherogenic    risk factors).&#91;12&#93;</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Exclusion criteria</b>    Pregnancy or breastfeeding, severe limitations or diseases impeding treadmill    exercise, baseline ECG with complete left bundle branch block.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Ethical considerations</b>    The study was evaluated and approved by the ethics committee in each participating    institution and written informed consent was obtained from all patients.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Study variables</b>    A clinical record was created that included personal data, information from    an in-depth interview, and physical examination results. Laboratory tests were    performed for fasting blood glucose and blood lipid levels-total cholesterol,    triglycerides, low density lipoprotein (LDL) and high density lipoprotein (HDL)-the    results recorded in the history. American Diabetes Association criteria were    used for normative laboratory values (<a href="#t1">Table 1</a>).&#91;12&#93;</font></p>     <p><a name="t1"></a></p>     ]]></body>
<body><![CDATA[<p>&nbsp;</p>     <p align="center"><img src="/img/revistas/medicc/v14n1/04t01.jpg"></p>     <p>&nbsp;</p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Diagnostic tools</b>    gSPECT was performed with treadmill exercise using a modified Bruce protocol,    according to American Society of Nuclear Medicine standards, under stress and    rest conditions on different days.&#91;13&#93; Tomographs synchronized to the    ECG monitor were performed one hour after intravenous injection of 1110 MBq    (30 mCi) of <sup>99m</sup>Tc-MIBI (methoxy-isobutyl-isonitrile), using a Sopha    DS7 single-head SPECT gamma camera (Sopha Medical, France). For each patient,    the study involved 32 projections of 50 seconds each, in a 180-degree circular    orbit; this used a low-energy, high-resolution collimator, 20% energy window    centered at the 140-keV <sup>99m</sup>Tc photopeak. The studies obtained 256    images, with a 64 x 64 matrix. Images were processed on a Power Vision (SMV,    Canada) workstation, using Emory Cardiac Toolbox software (Emory University,    USA).&#91;13&#93;</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><i>Assessment of    myocardial perfusion</i>. Visual and quantitative examination was performed    of vertical long-axis, horizontal long-axis, and perpendicular short-axis slices,    as well as the 17 left ventricular segments on the polar map display, according    to guidelines developed jointly by the American Heart Association, American    College of Cardiology and Society of Nuclear Medicine.&#91;13&#93; Perfusion    defects were assessed for extent, intensity, reversibility and involvement of    one or more territories. They were classified as non-extensive (only one segment    involved) or extensive (two or more segments involved). Intensity was reported    as percentage uptake compared to the area of greatest uptake in the left ventricular    polar image (mild defect, from 60% to 69%; moderate, from 50% to 59%; and severe,    under 50%).&#91;13&#93; Reversibility was classified as total, partial or nil.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Positive gSPECT    was defined by segmental or regional uptake defects involving at least two sectors,    at less than 70% of maximum uptake level in the left ventricular polar image.    Totally reversible ones were considered ischemic patterns; partially reversible    ones were interpreted as areas in which scar tissue coexists or as intense ischemias.    Defects with uptake of less than 30% or from 30% to 49% that did not change    with rest were considered scars (necrotic).</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Negative gSPECT    was defined by absence of uptake defects of less than 70%. Slight defects that    did not change on rest in the inferior and anterior region were interpreted    as attenuations (diaphragmatic and mammary, respectively) and were considered    negative.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><i>Assessment of    left ventricular function</i>. The global left ventricular ejection fraction    was computed; values of &gt;50% were considered normal, according to Faber,    et al.&#91;14&#93; Ventricular systolic wall thickening was assessed using cinematic    display (visual) and parietal thickening map (quantitative). Regional wall motion    was also assessed to detect functional alterations such as left ventricular    akinesia, hypokinesia and dyskinesias.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><i>Coronary angiography</i>.    This was performed only on gSPECT-positive patients. Quantitative angiography    (femoral route) was used, and obstructions of <u>&gt;</u>50% were considered    clinically significant.&#91;15&#93;</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Finally, SMI was    defined by positive gSPECT results, with or without angiographic confirmation.</font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Statistical    analysis.</b> After testing, two groups were formed: gSPECT positive and gSPECT    negative. Descriptive statistics (mean and standard deviation) were calculated    in both groups for age, fasting blood glucose levels, length of time since DM    onset and lipid levels. Means were compared using the Student t-test for independent    data. P values of &lt;0.05 were considered significant. Classification trees    were created using CRT analysis.&#91;9&#93; GSPECT results were included as    a categorical dependent variable and lipid levels as continuous independent    variables. Optimal cutoff points for indicators of silent myocardial ischemia    were determined in the study population and independent variables were compared    by obtaining normalized values. SPSS 15.0 statistical software was used to compute    statistics.</font></p>     <p>&nbsp;</p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="3"><b>RESULTS</b></font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Mean age of the    220 type 2 diabetics studied was 59.9&#177;7.9 years. In the study population;    74.5% of patients were being treated with diet and oral hypoglycemic agents    and 68.6% had had DM for more than five years.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">GSPECT was positive    for SMI in 64 patients (29.1% of the study population) and negative in 156 (70.9%).    As can be seen in <a href="#t2">Table 2</a>, the groups did not differ with    regard to age or blood glucose levels. Mean values for length of time since    DM onset, total cholesterol, LDL and triglycerides were greater in gSPECT-positive    diabetics (p &lt; 0.05). Average HDL level was lower in this group (p &lt; 0.05).    Patients aged 50 to 59 years had the greatest percentage of SMI (56.3%).</font></p>     <p><a name="t2"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/medicc/v14n1/04t02.jpg"></p>     <p>&nbsp;</p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Among gSPECT-positive    patients, 68.4% had ischemia in two territories; 65% of ischemic defects were    moderate or severe reversible defects (moderate and severe ischemia). In two    cases, a non-reversible severe defect (necrosis) was reported. Functional analysis    showed a lower mean ejection fraction in the group with ischemia (51% vs. 62%;    p = 0.001). <a href="/img/revistas/medicc/v14n1/html/04f01.htm">Figure 1</a> shows gSPECT images    from a type 2 diabetic with SMI.</font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">In the 64 gSPECT-positive    patients who underwent coronary angiography, 60 (27.3% of the total study population)    were found to have stenosis of <u>&gt;</u>50% in one or more coronary vessels.    The remaining four cases had normal angiographic results (1.8% of the total    study population); of these, one had no angiographic lesions and three had non-significant    coronary lesions. Multivessel disease was found in 68.4% of the coronary angiographies.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><a href="#f2">Figure    2</a> displays the classification tree relating gSPECT results to blood lipid    levels of all type 2 diabetic patients included in the study. The model first    generated a cutoff point of <u>&lt;</u>44 mg/dL for HDL. Below this level, the    percentage of patients gSPECT positive for SMI increased to 66.2%. The tree    shows cutoff points for LDL of &gt;119.9 mg/dL, and for triglycerides of &gt;107.2    mg/dL. The combination of HDL <u>&lt;</u>44 mg/dL and triglycerides &gt;107.2    mg/dL was associated with the greatest increase in the percentage of patients    with SMI (80.4%). Using the same statistical method, HDL was found to be the    most important normalized independent variable for these combinations of factors.</font></p>     <p><a name="f2"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/medicc/v14n1/04f02.jpg"></p>     <p>&nbsp;</p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><a href="#f3">Figure    3</a> shows a second classification tree for men. Among male diabetics, 33.3%    were gSPECT positive for SMI. In this case, the most important normalized variable    was LDL&gt;100.8 mg/dL; the percentage of SMI increased to 64.7% in diabetic    men with higher LDL levels.</font></p>     <p><a name="f3"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/medicc/v14n1/04f03.jpg"></p>     ]]></body>
<body><![CDATA[<p>&nbsp;</p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><a href="#f4">Figure    4</a> shows the classification tree for women. Among female diabetics, 24.8%    were gSPECT positive for SMI. In this case, the most important normalized variable    was HDL, with a cutoff point of HDL <u>&lt;</u>44 mg/dL; among diabetic women,    66.7% with lower HDL levels had SMI.</font></p>     <p><a name="f4"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/medicc/v14n1/04f04.jpg"></p>     <p>&nbsp;</p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Although gSPECT-detected    SMI prevalence was slightly higher in men than in women, the difference was    not statistically significant (p = 0.162).</font></p>     <p>&nbsp;</p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="3"><b>DISCUSSION</b></font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Type 2 diabetics    are at high risk for developing SMI,&#91;1-3&#93; so current international guidelines    are geared toward early SMI detection and treatment in this particular patient    group.&#91;16,17&#93; This study using gSPECT found substantial occurrence of    ischemia in the population assessed, results that concur with those of other    researchers&#91;1-3,5&#93; and affirm the need for an approach tailored to this    subpopulation.</font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Over half the tests    confirmed multivessel disease, indicating lesion severity. Similar results were    obtained from gSPECT and angiography, the latter of which is the current gold    standard for diagnosis of coronary disease.&#91;8,18-20&#93;</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">If angiographic    studies are considered the gold standard, then four patients had false positive    results from gSPECT. However, it is important to note that myocardial perfusion    is a functional evaluation of the vascular bed in its totality, including the    state of microcirculation, while angiography is an anatomic study that only    provides information about the epicardial arteries.&#91;19&#93; Several studies    have confirmed the high negative predictive value of gSPECT and consider coronary    angiography unnecessary when SPECT is negative.&#91;21-23&#93; Hence, analysis    of lipid factors in this study is based on gSPECT results.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Analysis of study    variables found no important differences between gSPECT-positive and -negative    groups in mean values for age and fasting blood glucose. This is probably related    to the fact that the entire population consisted of type 2 diabetics under treatment    and for whom age of disease onset was in the same range. However, the SMI group    did have slightly higher fasting blood glucose levels. A limitation of this    study was the absence of testing for glycosylated hemoglobin, indispensible    for assessing blood glucose control.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Average time since    DM onset was greater in patients with SMI. However, since the study focused    on evaluating lipid levels as a predictor of risk for SMI, controlling for this    variable was not indicated, since dyslipidemia may in part be associated with    a longer time since disease onset. The results of the VERIFICA study precisely    estimated the rate of coronary events at five years in diabetic patients, using    the function adapted from REGICOR to calculate risk.&#91;24&#93; The Veterans    Affairs Diabetes Trial provides another example of the influence of time since    DM onset; it found that time from DM onset interacted with randomization in    such a way that patients who had DM for under 12 years benefited from intensive    control-decreasing their risk of cardiovascular disease-while those with a longer    history of DM did not.&#91;25&#93;</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Differences in    lipid profiles between the two groups were considerable. gSPECT-positive diabetics    had lower mean HDL levels than those who were gSPECT negative, while mean levels    for total cholesterol, LDL, and triglycerides were higher in gSPECT-positive    than in gSPECT-negative patients. These results are consistent with those reported    by other studies demonstrating an important relationship between lipid alterations    and SMI in type 2 diabetics.&#91;1,5,6,26&#93; For years now, international    associations have recommended that optimal control in type 2 diabetes requires    lipid levels lower than those considered normal in non-diabetics. Our results    support the applicability of these recommendations in Cuba.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Two strengths of    classification and regression trees are their simple graphical representation    and the compact format of natural language rules. An analysis based on these    offers some attractive characteristics: it permits identification of homogeneous    groups at low or high risk and facilitates development of rules for making predictions    about individual cases.&#91;9&#93;</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">CRT analysis used    in this study permitted clear identification of optimal levels at which the    percentage of patients with SMI in the study population began to increase. This    dramatically changes the cost-benefit ratio for using more sensitive but costly    diagnostic techniques, and we conclude that in our population, such techniques    would be justified in assessment of type 2 diabetics who present with HDL <u>&lt;</u>44    mg/dL and triglycerides &gt;107.2 mg/dL</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">The cutoff points    found, although not identical, did not deviate greatly from ranges established    as risk levels by the American Diabetes Association.&#91;12&#93; However, although    LDL and HDL cutoff values for SMI were slightly higher in our setting, predictive    levels for triglycerides were clearly lower. These levels could be considered    as suggestive of SMI in Cuban type 2 diabetics. Future research with larger    populations will be necessary.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Some international    authors have shown that in the general population, increased cholesterol is    a much more important atherogenic factor than triglycerides, to the extent that    hypertriglyceridemia is not unanimously considered to be a coronary risk factor.&#91;6&#93;    However, it has been demonstrated that in diabetic patients, particularly in    women, an increase in triglycerides is an important atherogenic factor,&#91;4&#93;    which demonstrates that this group of patients requires separate analysis. In    this study, total cholesterol was not an important predictor of SMI. The statistical    method selected triglycerides as an important predictor for silent ischemia,    coinciding with the results of other research.&#91;5&#93;</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">HDL was the most    important normalized variable for the total population and for female diabetics.    Several authors have reported low HDL levels in diabetic patients,&#91;5,6,27-30&#93;    and some have proposed HDL as an independent marker for atherosclerosis and    myocardial ischemia.&#91;6,7,26,27&#93; Other researchers have found a significant    difference in HDL levels between diabetic patients with SMI and those without,    and have demonstrated that HDL can be an independent predictor of IHD.&#91;28&#93;</font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Another optimal    cutoff point indicative of SMI was LDL &gt;100.8 mg/dL, which in men is the    most important variable. For many years, LDL has been considered the principal    lipid marker for estimating cardiovascular risk in type 2 diabetic patients.    The same elevated LDL cholesterol level triples cardiovascular risk in diabetics    in comparison with the non-diabetics.&#91;29,30&#93; The results of a meta-analysis    of 14 randomized trials of statin therapy by the Cholesterol Treatment Trialists'    Collaboration, showed that a one mmol/L decrease in LDL reduces the risk of    major vascular events (myocardial infarction or coronary death, stroke, need    for coronary revascularization) in approximately one fifth of high-risk patients,    independent of initial lipid profile or other characteristics. Among all participants    with DM, the proportional reduction in major vascular events per mmol/L decrease    in LDL was similar, independent of history of vascular disease, sex, age, treated    hypertension, body mass index (BMI), systolic or diastolic blood pressure, smoking    and glomerular filtration rate.&#91;30&#93; The foregoing affirms the importance    of intensive treatment of dyslipidemia in type 2 diabetic patients to prevent    development of cardiovascular disease and concurs with our finding that SMI    is more frequent in type 2 diabetics with LDL levels above the thresholds identified    by the American Diabetes Association.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">The most important    finding emerging from analysis by sex was a somewhat greater frequency of SMI    in men than in women. For the past several decades it has been stated that men    have a greater risk for developing cardiovascular diseases.&#91;5&#93; SMI predictive    cutoff points by sex differed little from those of the total population; although    in men, levels of the most important normalized variable (LDL) were somewhat    lower than those in the total study population. In women, predictive values    for HDL were identical to those for the total study population.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Previous studies    have evaluated blood lipid levels in relation to sex and age. Suka et al. studied    the influence of sex, age and BMI on total cholesterol levels&#91;31&#93; and    affirmed that average total cholesterol levels varied substantially with age    in men and in women. In that study, LDL levels were significantly associated    with age and BMI in participants of both sexes. Prevalence of LDL<u>&gt;</u>160    mg/dL was greatest in men aged 50 to 59 years and in women aged 60 to 69 years.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">The results of    the Suka study could explain why the most important normalized variables differed    between men and women in our study, in which average age was similar for both    sexes. Patients aged 50 to 59 years had the highest percentage of cases of SMI.    In this age group, men had higher LDL levels than women, and LDL was the most    important independent variable for men, while HDL was for women. The effect    of menopause on lipid metabolism may also be involved; lack of information on    menopausal status constitutes a study limitation.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Other studies,    like ours, have explored health issues using classification and regression trees,&#91;9,32-34&#93;    with interesting results. This statistical method can be employed with all types    of predictor variables-binary, nominal, ordinal, interval and ratio-facilitating    their use, which is why it is becoming more common in medical research. It must    be remembered that the combination of factors identified in this study is not    necessarily the only one, but is optimal according to the logic of the algorithm    that was used to develop this model. This is another limitation of our study,    upon which future studies could improve.</font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">A substantial contribution    of this study is the fact that for the indicators included (blood lipid levels),    some optimal cutoff points were observed that were predictive of SMI. These    cutoff points are specific to the study population, contributing to knowledge    on this subject in the Cuban diabetic population. Additionally, it was possible    to determine combinations of changes in lipids conferring a notable increase    in SMI risk; if confirmed in future studies in larger populations, these would    provide a non-invasive method to detect SMI in this subpopulation.</font></p>     <p>&nbsp;</p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="3"><b>CONCLUSIONS</b></font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">The combination    of low HDL and elevated triglycerides was a strong predictor for SMI in a population    of type 2 diabetics and the condition was present in a substantial proportion    of participants. The authors recommend confirmation of these findings with further    studies in larger populations of type 2 diabetics.</font></p>     <p>&nbsp;</p>     ]]></body>
<body><![CDATA[<p><font face="Verdana, Arial, Helvetica, sans-serif" size="3"><b>REFERENCES</b></font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">1. Evans JM, Barnett    KN, McMurdo ME, Morris AD. Reporting of diabetes on death certificates of 1872    people with type 2 diabetes in Tayside, Scotland. Eur J Public Health. 2008    Apr;18(2):201-3.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1833099&pid=S1555-7960201200010000400001&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2. Wackers FJ,    Young LH, Inzucchi SE, Chyun DA, Davey JA, Barrett EJ, et al. Detection of silent    myocardial ischemia in asymptomatic diabetic subjects. The DIAD study. Diabetes    Care. 2004 Aug;27(8):1954-61.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1833101&pid=S1555-7960201200010000400002&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">3. Sajadieh A,    Nielsen OW, Rasmussen V, Hein HO, Hansen JF. Prevalence and prognostic significance    of daily-life silent myocardial ischemia in middle-aged and elderly subjects    with no apparent heart disease. Eur Heart J. 2005 Jul;26(14):1402-9.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1833103&pid=S1555-7960201200010000400003&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">4. Zeman M, Z&aacute;k    A. &#91;Pathogenesis and significance of diabetic dyslipidemia&#93;. Cas Lek    Cesk. 2004;143(5):302-6. Czech.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1833105&pid=S1555-7960201200010000400004&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">5. Pe&ntilde;a    Y, Fern&aacute;ndez-Britto JE, Coca MA, Batista JF, Rochela LM. Niveles de l&iacute;pidos    en sangre y SPECT de perfusi&oacute;n mioc&aacute;rdica en pacientes diab&eacute;ticos    tipo 2 asintom&aacute;ticos &#91;Internet&#93;. Alasbimn Journal. 2006 Jul &#91;cited    2011 Jul&#93;;8(33). Available from: <a href="http://www2.alasbimnjournal.cl/alasbimn/CDA/imprime/0,1208,PRT%253D17528,00.html" target="_blank">http://www2.alasbimnjournal.cl/alasbimn/CDA/imprime/0,1208,PRT%253D17528,00.html</a>.    Spanish.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1833107&pid=S1555-7960201200010000400005&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">6. Yarnell JW,    Patterson CC, Sweetnam PM, Thomas HF, Bainton D, Elwood PC, et al. Do total    and high density lipoprotein cholesterol and triglycerides act independently    in the prediction of ischemic heart disease? Ten-year follow-up of Caerphilly    and Speedwell Cohorts. Arterioscler Thromb Vasc Biol. 2001 Aug;21(8):1340-5.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1833109&pid=S1555-7960201200010000400006&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">7. Nieto R, Mart&iacute;n    A, Pereztol O. Estudios gated-SPECT en cardiolog&iacute;a nuclear. Aspectos    t&eacute;cnicos. In: Castro-Beiras JM, editor. Cardiolog&iacute;a nuclear y    otras t&eacute;cnicas no invasivas de imagen en cardiolog&iacute;a. Madrid:    Medit&eacute;cnica; 2005. p. 115-21. Spanish.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1833111&pid=S1555-7960201200010000400007&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">8. Cas&aacute;ns-Tormo    I, Jurado-L&oacute;pez JA. Diagn&oacute;stico de la enfermedad coronaria mediante    gated-SPECT de perfusi&oacute;n mioc&aacute;rdica. Rev Esp Cardiol. 2008;8(Suppl    B):S15-24. Spanish.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1833113&pid=S1555-7960201200010000400008&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">9. Rojo JM. &Aacute;rboles    de clasificaci&oacute;n y regresi&oacute;n &#91;Internet&#93;. Madrid: Consejo    Superior de Investigaciones Cient&iacute;ficas; 2006 May &#91;cited 2011 Jul&#93;.    65 p. Available from: http://humanidad</font><font face="Verdana, Arial, Helvetica, sans-serif" size="2">es.cchs.csic.es/cshs/web_UAE/tutoriales/PDF/AnswerTree.pdf.    Spanish.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1833115&pid=S1555-7960201200010000400009&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Anuario Estad&iacute;stico    de salud 2009. Havana: Ministry of Public Health (CU); 2009 &#91;cited 2011    Jul&#93;. Available from: <a href="http://bvs.sld.cu/cgi-bin/wxis/anuario/?IsisScript=anuario/iah.xis&tag5003=anuario&tag5021=e&tag6000=B&tag5013=GUEST&tag5022=2009" target="_blank">http://bvs.sld.cu/cgi-bin/wxis/anuario/?IsisScript=anuario/iah.xis&amp;tag    5003=anuario&amp;tag5021=e&amp;tag6000=B&amp;tag5013=GUEST&amp;tag5022=2009</a>.    Spanish.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1833117&pid=S1555-7960201200010000400010&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">11. O'Donnell CJ,    Elosua R. Factores de riesgo cardiovascular. Perspectivas derivadas del Framingham    Heart Study. Rev Esp Cardiol. 2008 Mar;61(3):299-310. Spanish.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1833119&pid=S1555-7960201200010000400011&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">12. American Diabetes    Association. Standards of medical care in diabetes&#151;2009. Diabetes Care.    2009 Jan;32 Suppl 1:S13-61.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1833121&pid=S1555-7960201200010000400012&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Committee on    Advanced Cardiac Imaging and Technology, Council on Clinical Cardiology, American    Heart Association; Cardiovascular Imaging Committee, American College of Cardiology;    and Board of Directors, Cardiovascular Council, Society of Nuclear Medicine.    Standardization of cardiac tomographic imaging. Circulation. 1992;86:338-9.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1833123&pid=S1555-7960201200010000400013&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Faber TL, Cooke    CD, Folks RD, Vansant JP, Nichols KJ, De Puey EG, et al. Left ventricular function    and perfusion from gated SPECT perfusion images: an integrated method. J Nucl    Med. 1999;40:650-9.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1833125&pid=S1555-7960201200010000400014&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Smith SC Jr,    Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ, et al. ACC/AHA Guidelines    for Percutaneous Coronary Intervention (Revision of the 1993 PTCA Guidelines).    A Report of the American College of Cardiology/American Heart Association Task    Force on Practice Guidelines (Committee to Revise the 1993 Guidelines for Percutaneous    Transluminal Coronary Angioplasty) Endorsed by the Society for Cardiac Angiography    and Interventions. Circulation. 2001 Jun 19;103(24):3019-41.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1833127&pid=S1555-7960201200010000400015&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">16. American Diabetes    Association. Standards of medical care for patients with diabetes mellitus.    Diabetes Care. 2002 Jan;25 Supp1 1:S33-49.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1833129&pid=S1555-7960201200010000400016&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Pasternak RC.    Report of the Adult Treatment Panel III: The 2001 National Cholesterol Education    Program guidelines on the detection, evaluation and treatment of elevated cholesterol    in adults. Cardiol Clin. 2003 Aug;21(3):393-8.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1833131&pid=S1555-7960201200010000400017&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Koehli M, Monbaron    D, Prior JO, Calcagni ML, Fivaz-Arbane M, Stauffer JC, et al. SPECT myocardial    perfusion imaging: long-term prognostic value in diabetic patients with and    without coronary artery disease. Nuklearmedizin. 2006;45(2):74-81.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1833133&pid=S1555-7960201200010000400018&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Go V, Bhatt    MR, Hendel RC. The diagnostic and prognostic value of ECG-gated SPECT myocardial    perfusion imaging. J Nucl Med. 2004 May;45(5):912-21.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1833135&pid=S1555-7960201200010000400019&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Pe&ntilde;a    Y, Coca MA, Batista JF, Fern&aacute;ndez-Britto JE, Quesada R, Pe&ntilde;a A.    Utilidad de la tomograf&iacute;a computarizada de emisi&oacute;n de fot&oacute;n    &uacute;nico sincronizada con el electrocardiograma para la detecci&oacute;n    de isquemia mioc&aacute;rdica silente en diab&eacute;ticos tipo 2. Rev M&eacute;d    Chile. 2009;137:1023-30. Spanish.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1833137&pid=S1555-7960201200010000400020&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Emmett L, Iwanochko    RM, Freeman MR, Barolet A, Lee DS, Husain M. Reversible regional wall motion    abnormalities on exercise technetium-99m-gated cardiac single photon emission    computed tomography predict high-grade angiographic stenoses. J Am College of    Cardiology. 2002;39:991-8.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1833139&pid=S1555-7960201200010000400021&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">22. Candell-Riera    J, De Le&oacute;n G, Jurado-L&oacute;pez JA, Diego-Dom&iacute;nguez M, Albert-Bertrand    FX, Coma-Canellae I. Evidencias cl&iacute;nicas y recomendaciones del gated-SPECT    de perfusi&oacute;n mioc&aacute;rdica. Rev Esp Cardiol. 2008;8 Suppl:58B-64.    Spanish.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1833141&pid=S1555-7960201200010000400022&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">23. Pe&ntilde;a    QY, Fern&aacute;ndez-Britto JE, Bacallao J, Batista JF, Coca MA, Toirac N, et    al. Diagn&oacute;stico de isquemia mioc&aacute;rdica silente en diab&eacute;ticos    tipo 2 mediante electrocardiograma, ergometr&iacute;a y Gated-SPECT &#91;Internet&#93;.    Rev Cubana Invest Biom&eacute;d. 2008 Jul-Dec &#91;cited 2011 May&#93;;27(3-4).    Available from: <a href="http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-03002008000300004&lng=es&nrm=iso&tlng=es" target="_blank">http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0864-03002008000300004&amp;lng=es&amp;nrm=iso&amp;tlng=es</a>.    Spanish.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1833143&pid=S1555-7960201200010000400023&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Marrugat J,    Subirana I, Com&iacute;n E, Cabezas C, Vila J, Elosua R, et al. Validity of    an adaptation of the Framingham cardiovascular risk function: the VERIFICA Study.    J Epidemiol Community Health. 2007 Jan;61(1):40-7.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1833145&pid=S1555-7960201200010000400024&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">25. Skyler JS,    Bergenstal R, Bonow RO, Buse J, Beedwania P, Gale EA, et al. Intensive glycemic    control and the prevention of cardiovascular events: implications of the ACCORD,    ADVANCE and VA diabetes trials. A position statement of the American Diabetes    Association and a scientific statement of the American College of Cardiology    Foundation and the American Heart Association. Diabetes Care. 2009 Jan;32(1):187-92.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1833147&pid=S1555-7960201200010000400025&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">26. Salama I, S&aacute;nchez    GA. Factores de riesgo y complicaciones cr&oacute;nicas en el diagn&oacute;stico    reciente de la Diabetes tipo 2. Rev Cubana Endocrinol. 2001;12(2):76-81. Spanish.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1833149&pid=S1555-7960201200010000400026&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">27. Gazzaruso C,    Garzaniti A, Giordanetti S, Falcone C, Fratino P. Silent coronary artery disease    in type 2 diabetes mellitus: the role of Lipoprotein(a), homocysteine and apo(a)    polymorphism. Cardiovasc Diabetol. 2002 Nov 22;1:5.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1833151&pid=S1555-7960201200010000400027&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">28. El Harchaoui    K, Arsenault BJ, Franssen R, Despr&eacute;s JP, Hovingh GK, Stroes ES, et al.    High-density lipoprotein particle size and concentration and coronary risk.    Ann Intern Med. 2009 Jan 20;150(2):84-93.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1833153&pid=S1555-7960201200010000400028&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">29. American Diabetes    Association. Management of dyslipidemia in adults with diabetes. Diabetes Care.    2003 Jan;26 Suppl 1:S83-6.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1833155&pid=S1555-7960201200010000400029&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">30. Cholesterol    Treatment Trialists' (CTT) Collaborators; Kearney PM, Blackwell L, Collins R,    Keech A, Simes J, et al. Efficacy of cholesterol-lowering therapy in 18,686    people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet.    2008 Jan 12;371(9607):117-25.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1833157&pid=S1555-7960201200010000400030&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">31. Suka M, Yoshida    K, Yamauchi K. Impact of Body Mass Index on Cholesterol Levels of Japanese Adults.    Intl J Clin Pract. 2006;60(7):770-82.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1833159&pid=S1555-7960201200010000400031&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">32. Bacallao Gallestey    J, Parapar de la Riestra JM, Roque M, Bacallao Guerra J. &Aacute;rboles de regresi&oacute;n    y otras opciones metodol&oacute;gicas aplicadas a la predicci&oacute;n del rendimiento    acad&eacute;mico. Educ Med Sup. 2004;18(3). Spanish.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1833161&pid=S1555-7960201200010000400032&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">33. Cha SH, Tappert    C. A genetic algorithm for constructing compact binary decision trees. J Pattern    Recognition Res. 2009;4(1):1-13.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1833163&pid=S1555-7960201200010000400033&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">34. Metsvaht T,    Pisarev H, Ilmoja ML, Parm U, Maipuu L, Merila M, et al. Clinical parameters    predicting failure of empirical antibacterial therapy in early onset neonatal    sepsis, identified by classification and regression tree analysis. BMC Pediatr.    2009 Nov 24;9:72.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1833165&pid=S1555-7960201200010000400034&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <p>&nbsp;</p>     ]]></body>
<body><![CDATA[<p>&nbsp;</p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Submitted: May    2, 2011    <br>   Approved for publication: January 4, 2012    <br>   Disclosures: None</font></p>      ]]></body><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Barnett]]></surname>
<given-names><![CDATA[KN]]></given-names>
</name>
<name>
<surname><![CDATA[McMurdo]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Morris]]></surname>
<given-names><![CDATA[AD.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Reporting of diabetes on death certificates of 1872 people with type 2 diabetes in Tayside, Scotland]]></article-title>
<source><![CDATA[Eur J Public Health.]]></source>
<year>2008</year>
<month> A</month>
<day>pr</day>
<volume>18</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>201-3</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wackers]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Young]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Inzucchi]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Chyun]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Davey]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Barrett]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Detection of silent myocardial ischemia in asymptomatic diabetic subjects: The DIAD study]]></article-title>
<source><![CDATA[Diabetes Care.]]></source>
<year>2004</year>
<month> A</month>
<day>ug</day>
<volume>27</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1954-61</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sajadieh]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Nielsen]]></surname>
<given-names><![CDATA[OW]]></given-names>
</name>
<name>
<surname><![CDATA[Rasmussen]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Hein]]></surname>
<given-names><![CDATA[HO]]></given-names>
</name>
<name>
<surname><![CDATA[Hansen]]></surname>
<given-names><![CDATA[JF.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Prevalence and prognostic significance of daily-life silent myocardial ischemia in middle-aged and elderly subjects with no apparent heart disease]]></article-title>
<source><![CDATA[Eur Heart J.]]></source>
<year>2005</year>
<month> J</month>
<day>ul</day>
<volume>26</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>1402-9</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zeman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zák]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Pathogenesis and significance of diabetic dyslipidemia]]></article-title>
<source><![CDATA[Cas Lek Cesk.]]></source>
<year>2004</year>
<volume>143</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>302-6</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peña]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández-Britto]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Coca]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Batista]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Rochela]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
</person-group>
<article-title xml:lang="es"><![CDATA[Niveles de lípidos en sangre y SPECT de perfusión miocárdica en pacientes diabéticos tipo 2 asintomáticos]]></article-title>
<source><![CDATA[Alasbimn Journal.]]></source>
<year>2006</year>
<month> J</month>
<day>ul</day>
<volume>8</volume>
<numero>33</numero>
<issue>33</issue>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yarnell]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Patterson]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[Sweetnam]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[HF]]></given-names>
</name>
<name>
<surname><![CDATA[Bainton]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Elwood]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
<name>
<surname><![CDATA[et]]></surname>
<given-names><![CDATA[al.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Do total and high density lipoprotein cholesterol and triglycerides act independently in the prediction of ischemic heart disease?: Ten-year follow-up of Caerphilly and Speedwell Cohorts]]></article-title>
<source><![CDATA[Arterioscler Thromb Vasc Biol.]]></source>
<year>2001</year>
<month> A</month>
<day>ug</day>
<volume>21</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1340-5</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nieto]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Martín]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pereztol]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
</person-group>
<article-title xml:lang="es"><![CDATA[Estudios gated-SPECT en cardiología nuclear: Aspectos técnicos]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Castro-Beiras]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<source><![CDATA[Cardiología nuclear y otras técnicas no invasivas de imagen en cardiología]]></source>
<year>2005</year>
<page-range>115-21</page-range><publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Meditécnica]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Casáns-Tormo]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Jurado-López]]></surname>
<given-names><![CDATA[JA.]]></given-names>
</name>
</person-group>
<article-title xml:lang="es"><![CDATA[Diagnóstico de la enfermedad coronaria mediante gated-SPECT de perfusión miocárdica]]></article-title>
<source><![CDATA[Rev Esp Cardiol.]]></source>
<year>2008</year>
<volume>8</volume>
<numero>^sB</numero>
<issue>^sB</issue>
<supplement>B</supplement>
<page-range>S15-24</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rojo]]></surname>
<given-names><![CDATA[JM.]]></given-names>
</name>
</person-group>
<source><![CDATA[Árboles de clasificación y regresión]]></source>
<year>2006</year>
<month> M</month>
<day>ay</day>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Consejo Superior de Investigaciones Científicas]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="book">
<collab>Anuario Estadístico de salud</collab>
<source><![CDATA[]]></source>
<year>2009</year>
<month>20</month>
<day>09</day>
<publisher-loc><![CDATA[Havana ]]></publisher-loc>
<publisher-name><![CDATA[Ministry of Public Health]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[O'Donnell]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Elosua]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Factores de riesgo cardiovascular: Perspectivas derivadas del Framingham Heart Study]]></article-title>
<source><![CDATA[Rev Esp Cardiol.]]></source>
<year>2008</year>
<month> M</month>
<day>ar</day>
<volume>61</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>299-310</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<collab>American Diabetes Association</collab>
<article-title xml:lang="en"><![CDATA[Standards of medical care in diabetes-2009]]></article-title>
<source><![CDATA[Diabetes Care.]]></source>
<year>2009</year>
<month> J</month>
<day>an</day>
<volume>32</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>S13-61</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<collab>Committee on Advanced Cardiac Imaging and Technology</collab>
<collab>Council on Clinical Cardiology</collab>
<collab>American Heart Association</collab>
<collab>Cardiovascular Imaging Committee</collab>
<collab>American College of Cardiology</collab>
<collab>Society of Nuclear Medicine</collab>
<article-title xml:lang="en"><![CDATA[Standardization of cardiac tomographic imaging]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1992</year>
<volume>86</volume>
<page-range>338-9</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Faber]]></surname>
<given-names><![CDATA[TL]]></given-names>
</name>
<name>
<surname><![CDATA[Cooke]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
<name>
<surname><![CDATA[Folks]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Vansant]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Nichols]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[De Puey]]></surname>
<given-names><![CDATA[EG]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Left ventricular function and perfusion from gated SPECT perfusion images: an integrated method]]></article-title>
<source><![CDATA[J Nucl Med.]]></source>
<year>1999</year>
<volume>40</volume>
<page-range>650-9</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith SC]]></surname>
<given-names><![CDATA[Jr]]></given-names>
</name>
<name>
<surname><![CDATA[Dove]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Jacobs]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Kennedy]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Kereiakes]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Kern]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[ACC/AHA Guidelines for Percutaneous Coronary Intervention (Revision of the 1993 PTCA Guidelines). A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty) Endorsed by the Society for Cardiac Angiography and Interventions]]></article-title>
<source><![CDATA[Circulation.]]></source>
<year>2001</year>
<month> J</month>
<day>un</day>
<volume>103</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>3019-41</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<collab>American Diabetes Association</collab>
<article-title xml:lang="en"><![CDATA[Standards of medical care for patients with diabetes mellitus]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2002</year>
<month> J</month>
<day>an</day>
<volume>25</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>S33-49</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pasternak]]></surname>
<given-names><![CDATA[RC.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Report of the Adult Treatment Panel III: The 2001 National Cholesterol Education Program guidelines on the detection, evaluation and treatment of elevated cholesterol in adults]]></article-title>
<source><![CDATA[Cardiol Clin.]]></source>
<year>2003</year>
<month> A</month>
<day>ug</day>
<volume>21</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>393-8</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Koehli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Monbaron]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Prior]]></surname>
<given-names><![CDATA[JO]]></given-names>
</name>
<name>
<surname><![CDATA[Calcagni]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Fivaz-Arbane]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Stauffer]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[SPECT myocardial perfusion imaging: long-term prognostic value in diabetic patients with and without coronary artery disease]]></article-title>
<source><![CDATA[Nuklearmedizin]]></source>
<year>2006</year>
<volume>45</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>74-81</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Go]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Bhatt]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Hendel]]></surname>
<given-names><![CDATA[RC.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The diagnostic and prognostic value of ECG-gated SPECT myocardial perfusion imaging]]></article-title>
<source><![CDATA[J Nucl Med.]]></source>
<year>2004</year>
<month> M</month>
<day>ay</day>
<volume>45</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>912-21</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peña]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Coca]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Batista]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández-Britto]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Quesada]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Peña]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang="es"><![CDATA[Utilidad de la tomografía computarizada de emisión de fotón único sincronizada con el electrocardiograma para la detección de isquemia miocárdica silente en diabéticos tipo 2]]></article-title>
<source><![CDATA[Rev Méd Chile.]]></source>
<year>2009</year>
<volume>137</volume>
<page-range>1023-30</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Emmett]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Iwanochko]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Freeman]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Barolet]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Husain]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Reversible regional wall motion abnormalities on exercise technetium-99m-gated cardiac single photon emission computed tomography predict high-grade angiographic stenoses]]></article-title>
<source><![CDATA[J Am College of Cardiology.]]></source>
<year>2002</year>
<volume>39</volume>
<page-range>991-8</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Candell-Riera]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[De León]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Jurado-López]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Diego-Domínguez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Albert-Bertrand]]></surname>
<given-names><![CDATA[FX]]></given-names>
</name>
<name>
<surname><![CDATA[Coma-Canellae]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
</person-group>
<article-title xml:lang="es"><![CDATA[Evidencias clínicas y recomendaciones del gated-SPECT de perfusión miocárdica]]></article-title>
<source><![CDATA[Rev Esp Cardiol.]]></source>
<year>2008</year>
<volume>8</volume>
<numero>^s58B-64</numero>
<issue>^s58B-64</issue>
<supplement>58B-64</supplement>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peña]]></surname>
<given-names><![CDATA[QY]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández-Britto]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Bacallao]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Batista]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Coca]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Toirac]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang="es"><![CDATA[Diagnóstico de isquemia miocárdica silente en diabéticos tipo 2 mediante electrocardiograma, ergometría y Gated-SPECT [Internet]]]></article-title>
<source><![CDATA[Rev Cubana Invest Bioméd.]]></source>
<year>2008</year>
<month> J</month>
<day>ul</day>
<volume>27</volume>
<numero>3-4</numero>
<issue>3-4</issue>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marrugat]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Subirana]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Comín]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Cabezas]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Vila]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Elosua]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Validity of an adaptation of the Framingham cardiovascular risk function: the VERIFICA Study]]></article-title>
<source><![CDATA[J Epidemiol Community Health.]]></source>
<year>2007</year>
<month> J</month>
<day>an</day>
<volume>61</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>40-7</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Skyler]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Bergenstal]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bonow]]></surname>
<given-names><![CDATA[RO]]></given-names>
</name>
<name>
<surname><![CDATA[Buse]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Beedwania]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gale]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE and VA diabetes trials. A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association]]></article-title>
<source><![CDATA[Diabetes Care.]]></source>
<year>2009</year>
<month> J</month>
<day>an</day>
<volume>32</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>187-92</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salama]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
</person-group>
<article-title xml:lang="es"><![CDATA[Factores de riesgo y complicaciones crónicas en el diagnóstico reciente de la Diabetes tipo 2]]></article-title>
<source><![CDATA[Rev Cubana Endocrinol.]]></source>
<year>2001</year>
<volume>12</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>76-81</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gazzaruso]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Garzaniti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Giordanetti]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Falcone]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Fratino]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Silent coronary artery disease in type 2 diabetes mellitus: the role of Lipoprotein(a), homocysteine and apo(a) polymorphism]]></article-title>
<source><![CDATA[Cardiovasc Diabetol.]]></source>
<year>2002</year>
<month> N</month>
<day>ov</day>
<volume>22</volume>
<page-range>5</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[El Harchaoui]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Arsenault]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Franssen]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Després]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Hovingh]]></surname>
<given-names><![CDATA[GK]]></given-names>
</name>
<name>
<surname><![CDATA[Stroes]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[High-density lipoprotein particle size and concentration and coronary risk]]></article-title>
<source><![CDATA[Ann Intern Med.]]></source>
<year>2009</year>
<month> J</month>
<day>an</day>
<volume>150</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>84-93</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<collab>American Diabetes Association</collab>
<article-title xml:lang="en"><![CDATA[Management of dyslipidemia in adults with diabetes]]></article-title>
<source><![CDATA[Diabetes Care.]]></source>
<year>2003</year>
<month> J</month>
<day>an</day>
<volume>26</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>S83-6</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kearney]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Blackwell]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Collins]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Keech]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Simes]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<collab>Cholesterol Treatment Trialists'</collab>
<article-title xml:lang="en"><![CDATA[Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2008</year>
<month> J</month>
<day>an</day>
<volume>371</volume>
<numero>9607</numero>
<issue>9607</issue>
<page-range>117-25</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Suka]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Yoshida]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Yamauchi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Impact of Body Mass Index on Cholesterol Levels of Japanese Adults]]></article-title>
<source><![CDATA[Intl J Clin Pract.]]></source>
<year>2006</year>
<volume>60</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>770-82</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bacallao Gallestey]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Parapar de la Riestra]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Roque]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bacallao Guerra]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang="es"><![CDATA[Árboles de regresión y otras opciones metodológicas aplicadas a la predicción del rendimiento académico]]></article-title>
<source><![CDATA[Educ Med Sup.]]></source>
<year>2004</year>
<volume>18</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cha]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Tappert]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A genetic algorithm for constructing compact binary decision trees]]></article-title>
<source><![CDATA[J Pattern Recognition Res.]]></source>
<year>2009</year>
<volume>4</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-13</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Metsvaht]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Pisarev]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ilmoja]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Parm]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Maipuu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Merila]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Clinical parameters predicting failure of empirical antibacterial therapy in early onset neonatal sepsis, identified by classification and regression tree analysis]]></article-title>
<source><![CDATA[BMC Pediatr.]]></source>
<year>2009</year>
<month> N</month>
<day>ov</day>
<volume>9</volume>
<page-range>72</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
